Aligos Therapeutics, Inc. (ALGS) has reported recent business progress and outlined continued advancement across its pipeline of drug candidates purpose-built for liver and viral diseases.
For the fourth quarter of 2025, the company incurred a net loss of $19.9 million or basic and diluted net loss per common share of $(1.91), compared with a net loss of $82.2 million or basic and diluted net loss per common share of $(13.08) in the same quarter of 2024.
For the full year 2025, the company's net loss narrowed to $24.2 million, or basic and diluted net loss per common share of $(2.45), improving from a net loss of $131.2 million, or basic and diluted net loss per common share of $(20.94) in 2024.
The company's pipeline includes Pevifoscorvir sodium, ALG-055009, ALG-097558 and ALG-170675, which are advancing through clinical and preclinical development.
Pevifoscorvir sodium is a capsid assembly modulator (CAM-E) being developed as a monotherapy for chronic hepatitis B virus (HBV) infection. The candidate is currently in Phase 2 B-SUPREME study, which includes both HBeAg- negative and HBeAg positive patients. The first interim analysis, involving about 60% (36) HBeAg- participants completing 12 weeks of treatment, was reached in Q4 2025, while a second interim analysis, with 50% (55) HBeAg+ participants completing 24 weeks, was reached in January 2026. Topline data for both cohorts are expected in 2027.
ALG-055009 is an experimental drug being tested for liver disease and obesity. Recent animal studies showed that when combined with weight loss drugs like Semaglutide or Tirzepatide, it led to even greater fat loss-up to 39-40% of body weight, compared to using those drugs alone. Importantly, the extra weight loss came from fat, not muscle, suggesting ALG-055009 could boost the effects of existing treatments. The company is exploring options to continue development, including possible partnerships.
ALG-097558 is an antiviral drug in Phase 2 trials for COVID-19, designed to be stronger than Paxlovid and doesn't need Ritonavir boosting. Early studies showed it worked broadly against coronaviruses like SARS and MERS, and it has been well tolerated in humans. Ongoing trials in the UK and US., backed by NIH funding, are testing its use in high-risk patients and special populations, with results expected as studies progress.
ALG-170675 is an antisense oligonucleotide (ASO) therapy for chronic HBV infection. The program remains in preclinical development, with early studies focused on reducing viral protein expression and advancing toward first-in-human testing.Aligos continues to expand its discovery efforts, including a program targeting hepatitis delta virus (HDV) with an ASO approach, which is currently in the discovery stage.
The company ended December 31, 2025, with $77.8 million in cash, cash equivalents and investments, which are expected to provide sufficient funding for planned operations into the third quarter of 2026.
ALGS has traded between $3.76 and $14.43 over the past year. The stock closed Thursday's trading at $6.66, down 2.92%. In afterhours trading, it slipped a further 5.41%, to $6.30.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.